|Rat Target Sites||Mouse Target Sites||TD50 (mg/kg/day)|
|hmo nrv per||nrv sto||hag lun||hag hmo lun mgl ute||21.3m,v||63.7m|
Key to the Table Above
The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.
For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.
Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.
TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.
A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.
Chemical (Synonym) CAS # Species Sex Strain Route Xpo+Xpt PaperNum 0 Dose 1 Dose 2 Dose 3 Dose Literature Reference or NCI/NTP:Site Path Site Path Notes TD50 DR Pval AuOp LoConf UpConf Cntrl 1 Inc 2 Inc 3 Inc Brkly Code
ETHYLENE OXIDE (EO) 75-21-8 2740 M f b6c inh 24m24 TR326 : 0 27.8mg 55.6mg MXB MXB 39.2mg * P<.002 21.7mg 163.mg 13/50 22/50 43/50 duo:mno; hag:pcy; kid:mno; lun:a/a,a/c; mds:mno; mgl: acn,adq; mln:mno; mul:mlh,mno; spl:mno; ute:acn,adn,mno. M MXB MXB 45.8mg * P<.0005 27.3mg 120.mg 3/50 9/50 26/50 hag:pcy; lun:a/a,a/c. C lun MXA 61.8mg * P<.0005 c 36.0mg 163.mg 2/50 5/50 22/50 lun:a/a,a/c. lun a/a 87.5mg * P<.002 c 47.0mg 362.mg 2/50 4/50 17/50 lun a/c 200.mg * P<.004 c 90.3mg 1.25gm 0/50 1/50 7/50 liv hpa 75.8mg \ P<.02 31.2mg 41.7gm 1/50 8/50 (3/50) S mgl MXA 76.3mg \ P<.02 p 31.5mg n.s.s. 1/50 8/50 (6/50) mgl:acn,adq. MXB MXB 79.2mg * P<.02 38.7mg n.s.s. 10/50 14/50 29/50 duo:mno; kid:mno; mds:mno; mgl:acn,adq; mln:mno; mul: mlh,mno; spl:mno; ute:acn,adn,mno. P MXA MXA 139.mg * P<.06 p 57.8mg n.s.s. 9/50 6/50 22/50 duo:mno; kid:mno; mds:mno; mln:mno; mul:mlh,mno; spl: mno; ute:mno. hag pcy 142.mg * P<.04 c 64.9mg n.s.s. 1/50 6/50 8/50 ute MXA 250.mg * P<.02 p 107.mg n.s.s. 0/50 2/50 5/50 ute:acn,adn. ute acn 297.mg * P<.02 p 120.mg n.s.s. 0/50 1/50 5/50 TBA MXB 103.mg * P<.4 27.6mg n.s.s. 30/50 33/50 46/50 liv MXB 149.mg \ P<.4 34.7mg n.s.s. 6/50 9/50 (3/50) liv:hpa,hpc,nnd. lun MXB 61.8mg * P<.0005 36.0mg 163.mg 2/50 5/50 22/50 lun:a/a,a/c. 2741 M m b6c inh 24m24 TR326 : 0 23.1mg 46.3mg MXB MXB 51.2mg * P<.04 22.5mg n.s.s. 12/50 26/50 29/50 hag:pcy; lun:a/a,a/c. C lun MXA 65.7mg * P<.06 c 27.8mg n.s.s. 11/50 19/50 26/50 lun:a/a,a/c. lun a/c 110.mg * P<.08 c 44.0mg n.s.s. 6/50 10/50 16/50 hag pcy 110.mg * P<.04 c 52.1mg n.s.s. 1/50 9/50 8/50 lun a/a 181.mg * P<.3 c 54.5mg n.s.s. 5/50 11/50 11/50 TBA MXB 108.mg * P<.5 24.4mg n.s.s. 29/50 38/50 41/50 liv MXB 273.mg * P<.6 53.7mg n.s.s. 15/50 17/50 21/50 liv:hpa,hpc,nnd. lun MXB 65.7mg * P<.06 27.8mg n.s.s. 11/50 19/50 26/50 lun:a/a,a/c. 2742 R m f34 inh 23m24 1624 () pool 0 5.42mg 10.8mg Lynch;txap,76,69-84;1984 per mso eis 30.8mg * P<.0005 + 18.3mg 77.8mg 3/78 9/79 21/79 bra gli eis 121.mg * P<.01 + 52.3mg 4.81gm 0/76 2/77 5/79 spl mnl eis 47.3mg * P<.3 + 14.3mg n.s.s. 24/77 38/79 30/76 liv nnd eis no dre P=1. 88.2mg n.s.s. 2/78 3/78 2/79 2743 R f fmf inh 76w78 1666m () pool 0 13.3mg Snellings;txap,75,105-117;1984/Garman 1985 pit ade ikr 29.8mg P<.08 - 8.48mg n.s.s. 2/40 4/20 bra mix ikr 237.mg * P<.6 + 24.7mg n.s.s. 1/40 0/20 0/20 1/20 2744 R f fmf inh 23m24 1666o () pool 0 1.31mg 4.32mg 13.2mg bra mix ir 143.mg * P<.02 + 61.7mg n.s.s. 0/154 1/78 3/79 3/79 2745 R m fmf inh 76w78 1666m () pool 0 9.29mg adr phe ikr 26.1mg P<.08 - 6.94mg n.s.s. 1/40 3/20 bra ast ikr 102.mg * P<.7 + 16.5mg n.s.s. 0/40 0/20 1/20 0/20 pit ade ikr no dre P=1. - 9.53mg n.s.s. 7/40 3/20 tes ict ikr no dre P=1. - 2.56mg n.s.s. 35/40 16/20 2746 R m fmf inh 24m25 1666o () pool 0 .916mg 3.02mg 9.25mg bra mix ir 70.7mg * P<.002 + 33.5mg 313.mg 1/156 1/79 4/78 7/79 2747 R f sda gav 25m35 1486 0 1.53mg 6.11mg Dunkelberg;bjca,46,924-933;1982 sto mix e 7.43mg * P<.0005 + 5.12mg 11.3mg 0/50 12/50 35/50 for sqc e 10.6mg * P<.0005 + 7.06mg 16.9mg 0/50 8/50 29/50 mgl adf e 10.0mg \ P<.02 - 4.33mg n.s.s. 4/50 13/50 (1/50)
See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.
A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.
For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.
The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.
A Supplementary Dataset gives details on dosing and survival for each experiment.
Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.
PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.